You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMiglitol
Accession NumberDB00491  (APRD01117)
TypeSmall Molecule
GroupsApproved
DescriptionMiglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet. In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.
Structure
Thumb
Synonyms
Glyset
Miglitol
Miglitolum
External Identifiers
  • Bay m 1099
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Glysettablet, film coated25 mg/1oralPharmacia And Upjohn Company Llc1996-12-18Not applicableUs
Glysettablet, film coated50 mg/1oralPharmacia And Upjohn Company Llc1996-12-18Not applicableUs
Glysettablet, film coated100 mg/1oralPharmacia And Upjohn Company Llc1996-12-18Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Miglitoltablet, coated25 mg/1oralOrient Pharma Co., Ltd.2015-07-31Not applicableUs
Miglitoltablet, coated50 mg/1oralOrient Pharma Co., Ltd.2015-07-31Not applicableUs
Miglitoltablet, coated100 mg/1oralOrient Pharma Co., Ltd.2015-07-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DiabanChen Ho
DiamigMicro DTF
DiasetACI
DiastabolSanofi-Aventis
ElitoxRanbaxy
EuglitolAbbott
GlycetPfizer
LaipingXinchang Pharmaceutical
MigboseStandard
MiglitBiocon
MignarGlenmark
MigtorTorrent
MisobitLupin
PlumarolLacer
SeibuleSanwa Kagaku
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0V5436JAQW
CAS number72432-03-2
WeightAverage: 207.2243
Monoisotopic: 207.110672659
Chemical FormulaC8H17NO5
InChI KeyInChIKey=IBAQFPQHRJAVAV-ULAWRXDQSA-N
InChI
InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1
IUPAC Name
(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
SMILES
OCCN1C[[email protected]](O)[C@@H](O)[[email protected]](O)[[email protected]]1CO
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as piperidines. These are compounds containing a piperidine ring, which is a saturated aliphatic six-member ring with one nitrogen atom and five carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassNot Available
Direct ParentPiperidines
Alternative Parents
Substituents
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Polyol
  • 1,2-diol
  • 1,2-aminoalcohol
  • Azacycle
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone.
PharmacodynamicsMiglitol, an oral alpha-glucosidase inhibitor, is a desoxynojirimycin derivative that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. As a consequence of plasma glucose reduction, miglitol reduce levels of glycosylated hemoglobin in patients with Type II (non-insulin-dependent) diabetes mellitus. Systemic nonenzymatic protein glycosylation, as reflected by levels of glycosylated hemoglobin, is a function of average blood glucose concentration over time. Because its mechanism of action is different, the effect of miglitol to enhance glycemic control is additive to that of sulfonylureas when used in combination. In addition, miglitol diminishes the insulinotropic and weight-increasing effects of sulfonylureas. Miglitol has minor inhibitory activity against lactase and consequently, at the recommended doses, would not be expected to induce lactose intolerance.
Mechanism of actionIn contrast to sulfonylureas, miglitol does not enhance insulin secretion. The antihyperglycemic action of miglitol results from a reversible inhibition of membrane-bound intestinal a-glucoside hydrolase enzymes. Membrane-bound intestinal a-glucosidases hydrolyze oligosaccharides and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. In diabetic patients, this enzyme inhibition results in delayed glucose absorption and lowering of postprandial hyperglycemia.
Related Articles
AbsorptionAbsorption of miglitol is saturable at high doses with 25 mg being completely absorbed while a 100-mg dose is only 50-70% absorbed. No evidence exists to show that systemic absorption of miglitol adds to its therapeutic effect.
Volume of distribution
  • 0.18 L/kg
Protein bindingThe protein binding of miglitol is negligible (<4.0%).
Metabolism

Miglitol is not metabolized in man or in any animal species studied.

Route of eliminationMiglitol is not metabolized in man or in any animal species studied. It is eliminated by renal excretion as an unchanged drug.
Half lifeThe elimination half-life of miglitol from plasma is approximately 2 hours.
ClearanceNot Available
ToxicityUnlike sulfonylureas or insulin, an overdose will not result in hypoglycemia. An overdose may result in transient increases in flatulence, diarrhea, and abdomi-nal discomfort. Because of the lack of extra-intestinal effects seen with miglitol, no serious systemic reactions are expected in the event of an overdose.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5422
Blood Brain Barrier-0.8379
Caco-2 permeable-0.7375
P-glycoprotein substrateSubstrate0.6354
P-glycoprotein inhibitor INon-inhibitor0.7325
P-glycoprotein inhibitor IINon-inhibitor0.8248
Renal organic cation transporterNon-inhibitor0.6749
CYP450 2C9 substrateNon-substrate0.8563
CYP450 2D6 substrateNon-substrate0.8168
CYP450 3A4 substrateNon-substrate0.6208
CYP450 1A2 substrateNon-inhibitor0.927
CYP450 2C9 inhibitorNon-inhibitor0.9022
CYP450 2D6 inhibitorNon-inhibitor0.9535
CYP450 2C19 inhibitorNon-inhibitor0.9676
CYP450 3A4 inhibitorNon-inhibitor0.9931
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9968
Ames testNon AMES toxic0.79
CarcinogenicityNon-carcinogens0.9702
BiodegradationNot ready biodegradable0.5392
Rat acute toxicity1.7432 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5797
hERG inhibition (predictor II)Non-inhibitor0.8756
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Tablet, coatedoral100 mg/1
Tablet, coatedoral25 mg/1
Tablet, coatedoral50 mg/1
Prices
Unit descriptionCostUnit
Glyset 100 mg tablet1.46USD tablet
Glyset 50 mg tablet1.24USD tablet
Glyset 25 mg tablet1.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point114 °CNot Available
water solubilitySolubleNot Available
logP-2.7Not Available
pKa5.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility610.0 mg/mLALOGPS
logP-2.3ALOGPS
logP-3.2ChemAxon
logS0.47ALOGPS
pKa (Strongest Acidic)12.9ChemAxon
pKa (Strongest Basic)7.6ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area104.39 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity48.16 m3·mol-1ChemAxon
Polarizability20.81 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA10BF02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (68.8 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Miglitol.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Miglitol.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Miglitol.
AmoxapineAmoxapine may increase the hypoglycemic activities of Miglitol.
AripiprazoleThe therapeutic efficacy of Miglitol can be decreased when used in combination with Aripiprazole.
Arsenic trioxideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Arsenic trioxide.
ArticaineThe therapeutic efficacy of Miglitol can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Miglitol can be decreased when used in combination with Asenapine.
AtazanavirThe therapeutic efficacy of Miglitol can be decreased when used in combination with Atazanavir.
BendroflumethiazideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypoglycemic activities of Miglitol.
BetamethasoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Betamethasone.
BrexpiprazoleThe therapeutic efficacy of Miglitol can be decreased when used in combination with Brexpiprazole.
BumetanideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Bumetanide.
BuserelinThe therapeutic efficacy of Miglitol can be decreased when used in combination with Buserelin.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Miglitol.
CeritinibThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ceritinib.
ChlorothiazideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Chlorothiazide.
ChlorpropamideMiglitol may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Chlorthalidone.
CitalopramCitalopram may increase the hypoglycemic activities of Miglitol.
ClomipramineClomipramine may increase the hypoglycemic activities of Miglitol.
ClozapineThe therapeutic efficacy of Miglitol can be decreased when used in combination with Clozapine.
CorticotropinThe therapeutic efficacy of Miglitol can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Miglitol can be decreased when used in combination with Cortisone acetate.
Cyproterone acetateThe therapeutic efficacy of Miglitol can be decreased when used in combination with Cyproterone acetate.
DabrafenibThe therapeutic efficacy of Miglitol can be decreased when used in combination with Dabrafenib.
DanazolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Danazol.
DapoxetineDapoxetine may increase the hypoglycemic activities of Miglitol.
DarunavirThe therapeutic efficacy of Miglitol can be decreased when used in combination with Darunavir.
DesogestrelThe therapeutic efficacy of Miglitol can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Dexamethasone.
DiazoxideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Diazoxide.
DienogestThe therapeutic efficacy of Miglitol can be decreased when used in combination with Dienogest.
DiflunisalDiflunisal may increase the hypoglycemic activities of Miglitol.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Miglitol.
DisopyramideMiglitol may increase the hypoglycemic activities of Disopyramide.
DrospirenoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Drospirenone.
EpinephrineThe therapeutic efficacy of Miglitol can be decreased when used in combination with Epinephrine.
EscitalopramEscitalopram may increase the hypoglycemic activities of Miglitol.
EstradiolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Estradiol.
Estrone sulfateThe therapeutic efficacy of Miglitol can be decreased when used in combination with Estrone sulfate.
Etacrynic acidThe therapeutic efficacy of Miglitol can be decreased when used in combination with Etacrynic acid.
Ethinyl EstradiolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ethinyl Estradiol.
Ethynodiol diacetateThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ethynodiol diacetate.
EtonogestrelThe therapeutic efficacy of Miglitol can be decreased when used in combination with Etonogestrel.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Miglitol.
EverolimusThe therapeutic efficacy of Miglitol can be decreased when used in combination with Everolimus.
FenfluramineFenfluramine may increase the hypoglycemic activities of Miglitol.
FludrocortisoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Fludrocortisone.
FluoxetineFluoxetine may increase the hypoglycemic activities of Miglitol.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Miglitol.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Miglitol.
FosamprenavirThe therapeutic efficacy of Miglitol can be decreased when used in combination with Fosamprenavir.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Miglitol.
FurosemideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Furosemide.
GliclazideMiglitol may increase the hypoglycemic activities of Gliclazide.
GlimepirideMiglitol may increase the hypoglycemic activities of Glimepiride.
GlipizideMiglitol may increase the hypoglycemic activities of Glipizide.
GlyburideMiglitol may increase the hypoglycemic activities of Glyburide.
GoserelinThe therapeutic efficacy of Miglitol can be decreased when used in combination with Goserelin.
HistrelinThe therapeutic efficacy of Miglitol can be decreased when used in combination with Histrelin.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Miglitol.
HydrochlorothiazideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Hydroflumethiazide.
Hydroxyprogesterone caproateThe therapeutic efficacy of Miglitol can be decreased when used in combination with Hydroxyprogesterone caproate.
IloperidoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Iloperidone.
IndalpineIndalpine may increase the hypoglycemic activities of Miglitol.
IndapamideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Indapamide.
IndinavirThe therapeutic efficacy of Miglitol can be decreased when used in combination with Indinavir.
Insulin AspartMiglitol may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirMiglitol may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineMiglitol may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineMiglitol may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanMiglitol may increase the hypoglycemic activities of Insulin Human.
Insulin LisproMiglitol may increase the hypoglycemic activities of Insulin Lispro.
IproclozideIproclozide may increase the hypoglycemic activities of Miglitol.
IproniazidIproniazid may increase the hypoglycemic activities of Miglitol.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Miglitol.
LanreotideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Lanreotide.
LanreotideMiglitol may increase the hypoglycemic activities of Lanreotide.
LeuprolideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Leuprolide.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Miglitol.
LevonorgestrelThe therapeutic efficacy of Miglitol can be decreased when used in combination with Levonorgestrel.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Miglitol.
LopinavirThe therapeutic efficacy of Miglitol can be decreased when used in combination with Lopinavir.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Miglitol.
LurasidoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Lurasidone.
MebanazineMebanazine may increase the hypoglycemic activities of Miglitol.
MecaserminMiglitol may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Miglitol can be decreased when used in combination with Medroxyprogesterone acetate.
Megestrol acetateThe therapeutic efficacy of Miglitol can be decreased when used in combination with Megestrol acetate.
MesalazineMesalazine may increase the hypoglycemic activities of Miglitol.
MestranolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Mestranol.
MethotrimeprazineThe therapeutic efficacy of Miglitol can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Methyclothiazide.
Methylene blueMethylene blue may increase the hypoglycemic activities of Miglitol.
MethylprednisoloneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Methylprednisolone.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Miglitol.
MetolazoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Metolazone.
MifepristoneMiglitol may increase the hypoglycemic activities of Mifepristone.
MilnacipranMilnacipran may increase the hypoglycemic activities of Miglitol.
MinaprineMinaprine may increase the hypoglycemic activities of Miglitol.
MoclobemideMoclobemide may increase the hypoglycemic activities of Miglitol.
NateglinideMiglitol may increase the hypoglycemic activities of Nateglinide.
NelfinavirThe therapeutic efficacy of Miglitol can be decreased when used in combination with Nelfinavir.
NiacinThe therapeutic efficacy of Miglitol can be decreased when used in combination with Niacin.
NialamideNialamide may increase the hypoglycemic activities of Miglitol.
NilotinibThe therapeutic efficacy of Miglitol can be decreased when used in combination with Nilotinib.
NorethisteroneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Norethisterone.
NorgestimateThe therapeutic efficacy of Miglitol can be decreased when used in combination with Norgestimate.
OctamoxinOctamoxin may increase the hypoglycemic activities of Miglitol.
OctreotideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Octreotide.
OctreotideMiglitol may increase the hypoglycemic activities of Octreotide.
OlanzapineOlanzapine may increase the hypoglycemic activities of Miglitol.
OxandroloneOxandrolone may increase the hypoglycemic activities of Miglitol.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Miglitol.
PaliperidoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Paliperidone.
PargylinePargyline may increase the hypoglycemic activities of Miglitol.
ParoxetineParoxetine may increase the hypoglycemic activities of Miglitol.
PasireotideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Pasireotide.
PasireotideMiglitol may increase the hypoglycemic activities of Pasireotide.
PegvisomantPegvisomant may increase the hypoglycemic activities of Miglitol.
PentamidineThe therapeutic efficacy of Miglitol can be decreased when used in combination with Pentamidine.
PentamidineMiglitol may increase the hypoglycemic activities of Pentamidine.
PhenelzinePhenelzine may increase the hypoglycemic activities of Miglitol.
PheniprazinePheniprazine may increase the hypoglycemic activities of Miglitol.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Miglitol.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Miglitol.
PiperazineThe therapeutic efficacy of Miglitol can be decreased when used in combination with Piperazine.
PipotiazineThe therapeutic efficacy of Miglitol can be decreased when used in combination with Pipotiazine.
PirlindolePirlindole may increase the hypoglycemic activities of Miglitol.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Miglitol.
PolythiazideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Polythiazide.
PrednisoloneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Prednisolone.
PrednisoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Prednisone.
ProgesteroneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Progesterone.
QuetiapineThe therapeutic efficacy of Miglitol can be decreased when used in combination with Quetiapine.
QuinethazoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Quinethazone.
QuinineMiglitol may increase the hypoglycemic activities of Quinine.
RasagilineRasagiline may increase the hypoglycemic activities of Miglitol.
RepaglinideMiglitol may increase the hypoglycemic activities of Repaglinide.
RisperidoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ritonavir.
SafrazineSafrazine may increase the hypoglycemic activities of Miglitol.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Miglitol.
SaquinavirThe therapeutic efficacy of Miglitol can be decreased when used in combination with Saquinavir.
SelegilineSelegiline may increase the hypoglycemic activities of Miglitol.
SertralineSertraline may increase the hypoglycemic activities of Miglitol.
SirolimusThe therapeutic efficacy of Miglitol can be decreased when used in combination with Sirolimus.
StanozololStanozolol may increase the hypoglycemic activities of Miglitol.
SulfadiazineMiglitol may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleMiglitol may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleMiglitol may increase the hypoglycemic activities of Sulfisoxazole.
SunitinibMiglitol may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe therapeutic efficacy of Miglitol can be decreased when used in combination with Tacrolimus.
TemsirolimusThe therapeutic efficacy of Miglitol can be decreased when used in combination with Temsirolimus.
TestosteroneTestosterone may increase the hypoglycemic activities of Miglitol.
TipranavirThe therapeutic efficacy of Miglitol can be decreased when used in combination with Tipranavir.
TolazamideMiglitol may increase the hypoglycemic activities of Tolazamide.
TolbutamideMiglitol may increase the hypoglycemic activities of Tolbutamide.
ToloxatoneToloxatone may increase the hypoglycemic activities of Miglitol.
TorasemideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Torasemide.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Miglitol.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Miglitol.
TrazodoneTrazodone may increase the hypoglycemic activities of Miglitol.
TriamcinoloneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Triamcinolone.
TrichlormethiazideThe therapeutic efficacy of Miglitol can be decreased when used in combination with Trichlormethiazide.
TriptorelinThe therapeutic efficacy of Miglitol can be decreased when used in combination with Triptorelin.
VilazodoneVilazodone may increase the hypoglycemic activities of Miglitol.
VorinostatThe therapeutic efficacy of Miglitol can be decreased when used in combination with Vorinostat.
VortioxetineVortioxetine may increase the hypoglycemic activities of Miglitol.
ZimelidineZimelidine may increase the hypoglycemic activities of Miglitol.
ZiprasidoneThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ziprasidone.
Food Interactions
  • Take with food, at beginning of each meal. Iron needs increased.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonistinhibitor
General Function:
Maltose alpha-glucosidase activity
Specific Function:
May serve as an alternate pathway for starch digestion when luminal alpha-amylase activity is reduced because of immaturity or malnutrition. May play a unique role in the digestion of malted dietary oligosaccharides used in food manufacturing.
Gene Name:
MGAM
Uniprot ID:
O43451
Molecular Weight:
209850.8 Da
References
  1. Mooradian AD, Thurman JE: Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29. [PubMed:9951949 ]
  2. Rossi EJ, Sim L, Kuntz DA, Hahn D, Johnston BD, Ghavami A, Szczepina MG, Kumar NS, Sterchi EE, Nichols BL, Pinto BM, Rose DR: Inhibition of recombinant human maltase glucoamylase by salacinol and derivatives. FEBS J. 2006 Jun;273(12):2673-83. [PubMed:16817895 ]
  3. Fukaya N, Mochizuki K, Tanaka Y, Kumazawa T, Jiuxin Z, Fuchigami M, Goda T: The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats. Eur J Pharmacol. 2009 Dec 10;624(1-3):51-7. doi: 10.1016/j.ejphar.2009.09.048. Epub 2009 Oct 7. [PubMed:19818342 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Maltose alpha-glucosidase activity
Specific Function:
Essential for the degradation of glygogen to glucose in lysosomes.
Gene Name:
GAA
Uniprot ID:
P10253
Molecular Weight:
105322.935 Da
References
  1. Fukaya N, Mochizuki K, Tanaka Y, Kumazawa T, Jiuxin Z, Fuchigami M, Goda T: The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats. Eur J Pharmacol. 2009 Dec 10;624(1-3):51-7. doi: 10.1016/j.ejphar.2009.09.048. Epub 2009 Oct 7. [PubMed:19818342 ]
  2. Hirata A, Igarashi M, Iwai H, Tominaga M: Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats. Horm Metab Res. 2009 Mar;41(3):213-20. doi: 10.1055/s-0028-1105919. Epub 2008 Dec 15. [PubMed:19085811 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Poly(a) rna binding
Specific Function:
Cleaves sequentially the 2 innermost alpha-1,3-linked glucose residues from the Glc(2)Man(9)GlcNAc(2) oligosaccharide precursor of immature glycoproteins.
Gene Name:
GANAB
Uniprot ID:
Q14697
Molecular Weight:
106873.125 Da
References
  1. Fukaya N, Mochizuki K, Tanaka Y, Kumazawa T, Jiuxin Z, Fuchigami M, Goda T: The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats. Eur J Pharmacol. 2009 Dec 10;624(1-3):51-7. doi: 10.1016/j.ejphar.2009.09.048. Epub 2009 Oct 7. [PubMed:19818342 ]
  2. Hirata A, Igarashi M, Iwai H, Tominaga M: Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats. Horm Metab Res. 2009 Mar;41(3):213-20. doi: 10.1055/s-0028-1105919. Epub 2008 Dec 15. [PubMed:19085811 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Maltose alpha-glucosidase activity
Specific Function:
Has alpha-glucosidase activity.
Gene Name:
GANC
Uniprot ID:
Q8TET4
Molecular Weight:
104333.445 Da
References
  1. Fukaya N, Mochizuki K, Tanaka Y, Kumazawa T, Jiuxin Z, Fuchigami M, Goda T: The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats. Eur J Pharmacol. 2009 Dec 10;624(1-3):51-7. doi: 10.1016/j.ejphar.2009.09.048. Epub 2009 Oct 7. [PubMed:19818342 ]
  2. Hirata A, Igarashi M, Iwai H, Tominaga M: Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats. Horm Metab Res. 2009 Mar;41(3):213-20. doi: 10.1055/s-0028-1105919. Epub 2008 Dec 15. [PubMed:19085811 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Chloride ion binding
Specific Function:
Not Available
Gene Name:
AMY2A
Uniprot ID:
P04746
Molecular Weight:
57706.51 Da
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23